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Abstract
Objective: To explore individuals’ experiences of daytime use of a day-and-night hybrid closed-loop system,
their information and support needs, and their views about how future systems could be improved.
Research Design and Methods: Twenty-four adults, adolescents, and parents were interviewed before using a
hybrid day-and-night closed-loop system and 3 months later, data were analyzed thematically.
Results: Participants praised the closed loop’s ability to respond to high and low blood glucose in ways which
extended beyond their own capabilities and to act as a safety net and mop up errors, such as when a mealtime
bolus was forgotten or unplanned activity was undertaken. Participants also described feeling less burdened by
diabetes as a consequence and more able to lead flexible, spontaneous lives. Contrary to their initial expec-
tations, and after trust in the system had been established, most individuals wanted opportunities to collaborate
with the closed loop to optimize its effectiveness. Such individuals expressed a need to communicate infor-
mation, such as when routines changed or to indicate different intensities of physical activity. While individuals
valued frequent contact with staff in the initial month of use, most felt that their long-term support needs would
be no greater than when using an insulin pump.
Conclusions: While participants reported substantial benefits to using the closed loop during the day, they also
identified ways in which the technology could be refined and education and training tailored to optimize
effective use. Our findings suggest that mainstreaming this technology will not necessarily lead to increased
demands on clinical staff.
Keywords: Type 1 diabetes, Closed-loop system, Artificial pancreas, Medical device, User experience, Qualitative
research.
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Introduction
Aclosed-loop system combines a real-time continuousglucose monitor (CGM) with an insulin pump and an al-
gorithm which translates, in real time, information from
the CGM and computes the amount of insulin delivered by the
pump. Closed-loop systems require varying levels of user in-
put; for example, to calibrate the CGM and enter information
about carbohydrate consumption. To improve usability and
acceptability, studies have elicited a user perspective.1–3 Many
have consulted individuals who have no direct experience of
using the technology1,3–6 and have found that, as well as having
high expectations, people question whether they will be able to
trust the system.3–5 This has prompted concerns that people’s
attitudes and expectations may present barriers to using the
technology.5 When studies have involved individuals who have
used the technology, they have mostly focused on overnight
systems7–12 and have found that participants generally perceive
glycemic and other benefits as outweighing logistical bur-
dens.7–10,12 However, findings cannot be extrapolated to 24-h
systems because insulin requirements and routines are more
stable and predictable overnight; this has prompted suggestions
that it may be easier to adapt to and trust overnight systems.7
Limited research has explored people’s experiences of
using 24-h systems. Studies have mostly been of very short
duration (3–5 days) with high levels of staff monitoring.2,13,14
Hence, there have been calls for longer studies to be under-
taken in ‘‘real world’’ settings.2,4,13 One exception is a mixed-
methods study involving adults, children, and adolescents who
used a closed-loop system for 12 weeks; although only adults
used the system during the day.15 While this study offers useful
insights, there was limited focus on daytime use, and data
reporting mostly cohered around perceived benefits and
burdens.15
Despite significant advances in the technology, there re-
mains limited understanding of how people engage with, and
use, 24-h systems in everyday life and over time. This infor-
mation is vital for understanding whether, and how, trust in the
system develops; what information and support individuals
may need to make effective use of the technology8; and, how
systems might be further improved to meet users’ needs. To
address these objectives, we report findings from interviews
undertaken with individuals who used a hybrid day-and-night
closed-loop system combined with pump suspend feature over
3 months. Given that studies have overwhelmingly focused
upon nighttime use, we focus our reporting on people’s ex-
periences of using the closed-loop system during the day.
Methods
Qualitative approaches are recommended when little is
known about the area under investigation. This is because
they allow findings to emerge from the data rather than
testing predetermined hypotheses; indeed, qualitative ap-
proaches are used to open up new areas of enquiry and gen-
erate hypotheses, which can then be tested quantitatively for
this reason.16,17 In this study, in-depth interviews informed
by topic guides were used as these enabled the discussion to
remain relevant to addressing the study objectives, while
affording flexibility for participants to raise and discuss is-
sues they perceived as salient, including those unanticipated
at the beginning of the study.18 Interviews also afforded
privacy so that participants could talk about sensitive topics
(e.g., criticisms of the support received during the trial)
should they choose to do so. Topic guides were developed in
light of literature reviews, input from patient representatives,
and clinical coinvestigators (see Table 1 for information
about the main areas explored in the interviews and how the
topic guides were used to facilitate discussion with partici-
pants). Data collection and analysis took place concurrently
so that findings identified in early interviews could be used to
inform the topics explored in later ones.
Table 1. Key Areas Explored in Baseline and Follow-up Interviews
Baseline interview
 Experiences of diabetes self-management before the trial
 Perceptions and understandings of the closed-loop system, including
B How it would work
B How it would impact on diabetes self-management practices
B Potential impact on blood glucose control
 Any worries and concerns about using a closed-loop system and the reasons for these
 Motivations and agendas for trial participation
Follow-up interview
 Initial experiences of using, and adapting to, the closed loop
 Confidence and trust in the system (was this established, if so why or why not?); reasons for disconnecting or
overriding the system
 Impact of using the closed-loop system on everyday work/school and family life
B Dietary choices
B Physical activity
B Approaches to managing and/or preventing hypoglycemia and hyperglycemia
B Self-concepts and relationships with others
B worries and concerns about having diabetes
 Views about how the closed loop could be improved to aid efficacy and acceptability
 Views about the training and support received during the trial (e.g., was it sufficient; how could it be improved?)
 Longer-term support needed to use the closed loop in routine clinical care
While the same general areas, outlined above, were covered with all participants, tailored questions were also asked and probes used to
encourage and enable a fuller elicitation of responses to particular questions. We also tailored some of the questions asked in each
participant’s follow-up interview to take account of the kinds of information and experiences they had shared in their baseline interview.
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Recruitment and data collection
Participants were recruited following randomization to a
3-month clinical trial (APCam11) designed to assess the ef-
fectiveness of a hybrid day-and-night closed-loop system
combined with pump suspend feature compared with sensor-
augmented pump therapy (control arm).19 For more detail
about the closed-loop system and training and contact re-
ceived during the trial see Table 2. To be eligible for this
trial, individuals had to have used an insulin pump for ‡3
months, a screening HbA1c ‡7.5% (58.5 mmol/mol) and
£10% (86 mmol/mol) and a diabetes duration of ‡6 months.19
Individuals randomized to a closed loop were invited to
opt-in to the interview study by staff in the four participating
U.K. sites. Participants comprised individuals ‡16 years of
age, individuals 13–15 years of age and their parent(s), and
parents of those £12 years of age; all individuals approached
agreed to take part. Recruitment continued until there was
adequate representation of different age groups and data
saturation had occurred; that is, until no new findings were
identified in new data collected. The study received approval
in the United Kingdom from Cambridge East Research Ethics
Committee (REC ref 15/EE/0324) and the Medicines &
Health Products Regulatory Agency.
Participants were interviewed before commencing use of
the closed-loop system (baseline) and 3 months later. This
design permitted initial expectations to be compared with
actual experiences of using the technology. Interviews were
conducted by M.B., an experienced qualitative researcher
who was not a member of the clinical team, at a time and
location of participants’ choosing (mostly in their own
homes). Interviews averaged 1–2 h, and were transcribed in
full. Before interviews were undertaken, it was made clear to
participants that the qualitative research team was indepen-
dent of the trial team and that all information shared would be
kept strictly confidential.
Data analysis
Interviews were analyzed by J.L. (an experienced quali-
tative researcher) and M.B. using a thematic approach in-
formed by the method of constant comparison. Interviews
were cross-compared to identify recurrent themes20; we also
explored differences and similarities in participants’ experi-
ences across different age groups and over time by comparing
baseline and follow-up accounts. A coding framework was
then developed by J.L. and M.B., which captured key find-
ings and themes and contextual information needed to aid
data interpretation. Nvivo, a qualitative software package,
was used to facilitate data coding and retrieval and coded
datasets were subjected to further analyses to allow more
nuanced interpretations of the data to be developed.
Results
The sample comprised 10 adults (‡18 years of age), 5
adolescents (13–17 years of age) and 9 parents. Interviewee
demographic data are presented in Table 3.
Below, we begin by reporting participants’ initial expec-
tations of the closed-loop system before describing their ac-
tual experiences of using this technology in everyday life;
this includes exploration of the perceived clinical and
quality-of-life benefits of using a closed loop and how, and
why, participants wanted to continue to take an active role in
diabetes management by collaborating with the system. We
conclude by reporting participants’ views about the training
and support received during the trial and their opinions about
the support needed to use a closed loop in the longer-term. As
all the main findings cut across the sample, our reporting has
not been separated out according to participant groups (e.g.,
adults, adolescents, and parents); however, we do indicate
when a particular issue was most keenly felt within one
particular group.
Initial expectations (baseline interviews)
Better and more stable glycemic control. At baseline, all
participants conveyed an understanding, informed by previ-
ous trial participation and/or reading about the technology
(e.g., in newspapers or online), that the closed loop would
help regulate blood glucose by bringing it down when it
started to go high and suspending or reducing the basal rate
when blood glucose started to drop: ‘‘It’s aiming to get rid of
the peaks and troughs, or to narrow the peaks and troughs as
much as possible’’ (Adult#4). Most also suggested that the
closed-loop would be better equipped to address high rather
than low blood glucose because, while it could administer
Table 2. Description of the Closed-Loop System and Trial Procedures
The FlorenceM closed-loop system utilized a model predictive control algorithm (version 0.3.46; University of
Cambridge, Cambridge, United Kingdom) residing on a smartphone (Galaxy S4; Samsung, South Korea). Every 10
minutes, the control algorithm calculated an insulin infusion rate, which was set on the study pump. The control
algorithm was initialized using preprogrammed basal insulin delivery downloaded from the study pump. Information
about the participant’s weight and total daily insulin dose were entered at setup. The treat-to-target control algorithm
aimed to achieve glucose levels between 5.8 and 7.3 mmol/L depending on the accuracy of model-based glucose
predictions.
Training and staff contact received during the trial:
The study included up to 11 visits and six telephone/email contacts for subjects completing the study. Participants
randomized to the closed-loop group attended the clinical research facility/usual clinic for a 2- to 3-h visit. Training
was provided on initiation and discontinuation of the hybrid closed-loop system, switching between closed loop and
standard insulin pump therapy, meal bolus procedure, and the use of study devices during exercise. A closed-loop
system user manual, including a trouble-shooting section, was handed out during the initial training session.
Competency on the use of the closed-loop system was assessed. Participants were contacted within 24 to 48 h after the
initiation of study treatment. During the first 2 weeks of the intervention, participants were contacted (the United
Kingdom) or seen (the United States) in the clinic weekly. Thereafter, participants were contacted monthly. All
participants were provided with a 24-h helpline to contact the study team in the event of study-related issues.
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insulin to lower blood glucose, once insulin was in one’s
system, ‘‘it can’t suck the insulin back out so if it’s like, if
you’ve bolused too much there is that risk still of a hypo’’
(Adult#8). Hence, while most people envisaged that they
would be able to step back and allow the closed loop to
regulate blood glucose on their behalf, they also anticipated
still needing to look out for, and treat, hypoglycemia. How-
ever, many were also hopeful that, because the closed-loop
system might detect and respond to blood glucose dropping
more quickly than they could, they would experience less
severe episodes of hypoglycemia (Table 4).
Probationary period. Despite having positive expecta-
tions, participants described feeling ambivalent about hand-
ing control over to the closed loop and speculated that, in the
initial days and weeks of use, they would be checking their
blood glucose regularly and disconnecting or overriding the
system if they had any doubts about how it was functioning.
Parents also noted how they would be keeping their child
under close supervision during this time: ‘‘I’m absolutely not
gonna let him out of my sight. I suppose its trust, you know,
it’s not just a broken leg. It’s his life. And it’s delivering
deadly insulin into my son, 24/7.’’ (Parent#2)
Using the closed-loop system (follow-up interviews)
Developing trust and confidence in the system. In keep-
ing with their initial expectations, participants, at follow-up,
described an initial probationary period, typically lasting
several weeks, when they had scrutinized the closed-loop
system’s graphs frequently to seek reassurance that it was
working in safe and effective ways: ‘‘Certainly the first week,
I was looking at the graphs sort of every five minutes
(laughing) saying: what’s it doing now. And I think after a
week of that, I was like: oh well, you know, I was still looking
at it frequently but less so.’’ (Adult#10)
Participants also described how, as a result of seeing the
closed loop making logical and sensible decisions, and re-
sponding to high/low blood glucose faster than they could
that, over time, they had felt more confident and able to allow
it to operate without constantly scrutinizing its actions: ‘‘You
can see it doing its job, and you can see how it’s doing it. And
I’ll be honest, I could see that it was doing a better job than I
could do myself.’’ (Adult#9)
Some individuals also described this initial adjustment
period as a two-way process wherein, while they were scru-
tinizing the system’s functioning, the closed loop was cali-
brating itself to their specific insulin requirements. During
this calibration period, some also noted how, in hindsight,
their own anxieties and resultant propensity to take action to
address high/low blood glucose might have been counter-
productive to the system’s learning. This included Adult#10
who described how, initially, ‘‘I did do my own correction if I
felt it wasn’t doing it fast enough’’ until they realized that, ‘‘it
wasn’t going to be helpful for it to work out what I actually
needed to be given for the corrections’’ and Parent#7 who
reported how:
‘‘obviously the artificial pancreas recognizes after a few days
his patterns. But I was interfering, because I was thinking: oh
my gosh, he’s going into hypo, this is crazy. And actually
when I stopped doing stuff and I allowed the artificial pancreas
to do its thing, it became a lot better.’’
Some participants, especially parents or those whose jobs
or other commitments meant that they did not follow rou-
tines, noted that their confidence in the system only devel-
oped after they had gained a full appreciation of how the
algorithm worked; specifically that it learnt insulin require-
ments by monitoring and using blood glucose data acquired
over several days of previous use. These individuals dis-
cussed how, once this understanding had been established,
they had better appreciated why blood glucose control could
be thrown out on atypical days; hence, they no longer worried
that the system was malfunctioning or tried to intervene to
correct or override it (Table 4).
Clinical and quality-of-life benefits
Lessening the burden of self-management. Participants
reported how using this technology had lessened the burden
of diabetes management as they had needed to do finger-prick
checks and administer corrective doses less frequently. This,
as participants further noted, had had a positive impact on
how they felt about having diabetes wherein: ‘‘it made me not
really care that I am diabetic’’ (Adolescent#4) or, ‘‘it’s def-
initely made a material difference to the amount of time I’ve
had to think about being a diabetic’’ (Adult#4). Parents also
noted an improvement in relationships with their children
because there had been less need to constantly remind them to
undertake self-management tasks, such as blood glucose
testing.
Table 3. Demographic Characteristics
of Study Participants
Participants with type 1 diabetes (n = 15)
Gender, female, n (%) 7 (46.7)
Age at recruitment (years)
13–17 5
18–30 1
31–40 6
41–50 2
51–60
60+ 1
Occupation/education, n (%)
Professional 5 (33.3)
Semiskilled 4 (26.7)
Retired 1 (6.7)
Higher education 2 (13.3)
Secondary school 3 (20)
Previous involvement in
closed-loop system trial(s)
6 (40)
Parents of pediatric patients (n = 9)a
Gender, female, n (%) 7 (77.8)
Age at recruitment (years)
31–40 2
41–50 5
51–60 2
Occupation, n (%)
Professional 5 (55.6)
Semiskilled 3 (33.3)
Unemployed/full-time carer 1 (11.1)
Child had previous involvement
in closed-loop system trial(s)
3 (33.3)
aThis includes parents who represented children £12 years of age
(n= 5) and parents of children 13–15 years of age (n= 4). In one
instance, both parents of a child 13–15 years of age participated in
an interview.
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Better blood glucose control. Participants also pointed to
the clinical and quality-of-life benefits of having, ‘‘somebody
else watching out for me, in the sense that I could have cor-
rections made to my blood sugars without me being aware’’
(Adult#10). Indeed, in line with their initial expectations,
participants reported experiencing better and more stable
blood glucose. This, as participants further noted, was be-
cause the closed-loop system had been able to provide a level
of responsiveness which had extended beyond their own
human capabilities, given the difficulties of keeping blood
glucose levels and insulin requirements under constant
scrutiny, especially when they were working or distracted by
other responsibilities during the day: ‘‘I’m a single parent and
I have to go to work. So I can’t live and breathe diabetes every
single day, every single minute of every hour. I don’t have the
time. But the artificial pancreas did.’’ (Parent#7)
Table 4. Participant Quotations
Theme and subtheme Participant quotations
Initial expectations (baseline line interviews): Better
and more stable glycemic control ‘‘So, if I was doing my cycle ride from here to the station I
know that it would switch off before I noticed that it was
going down really really quickly and maybe prevent a
bigger hypo. it may help sort of prevent the worry of a
really big one happening.’’ (Adult#3)
Using the closed-loop system (follow-up interviews):
Developing trust and confidence in the system ‘‘it has like a 3 day memory on it. So if you changed to like
when he went on holiday- in the school holidays- it took the
artificial pancreas a long time to readjust.. Before I didn’t
understand why he was going hypo, so I was trying to
interfere. As the trial got on and went further, I understood
its mindset- and- I understood what it was doing, and I could
deal with it better, if that makes sense. the more I
understood it, the more I could work with it, and the more I
could trust it.’’ (Parent#8)
Clinical and quality-of-life benefits: A more flexible
and active life ‘‘it probably has helped a lot because, as far as my sugar
levels were concerned, eating and anything else, I could get
away with putting it off a little bit longer, because I knew
that if my sugar levels were starting to go down a little bit
the closed-loop system could deal with that.? So I could put
off having something to eat for an extra 30 minutes or an
extra 60 minutes. So in that regards yeah, it was a lot better
for me personally.’’ (Adult#1)
‘‘if I’ve gone for a bit of unplanned exercise, or I’ve been a
bit more active than I would normally be I’ve not really
logged it as exercise, then the closed-loop drops the insulin,
the basal flow, to account for that, which then keeps the
blood sugar back in range again. And otherwise, if I’d
hadn’t remembered to change my basal rate, I’d have had a
low.’’ (Adult#4)
Views about education and training and need for staff
support: Training and support needs during the
3-month trial
‘‘I wouldn’t have probably learnt as much about it as I did if
I hadn’t been able to question them. If they’d told me
everything that I’ve learnt on the first week or two, I would
have forgotten it by now. By actually being in contact with
them and learning it as I’ve been going along, I’ve
maintained the information a lot more. [because] you
don’t necessarily remember it until you’ve actually
experienced or you’ve drilled it in. It’s like going through
university. You go to your lecture. And unless you go and
do a bit more research you forget most of it.’’ (Adult#9)
‘‘It’s learning how to use all the features properly. But also
maintaining a memory of what the different features are
because some people are not going to require the exercise
feature at all, whereas I needed to use it on a daily basis to
take the dog for a walk and first thing in the morning for
work. That was all- all those things we figured out within
the first couple of weeks. So I learnt that those features were
required.’’ (Adult#1)
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Reassurance and less worry. Participants also noted
gaining reassurance from the closed loop being able to ‘‘mop
up’’ errors, such as when they had miscounted the carbohy-
drate content of meals or forgotten to administer insulin be-
fore eating: ‘‘if I forget to bolus I don’t have- I’ve not got
anything covering my back. I’ve just got to do what I think’s
right, whereas the [closed-loop] actually made a lot of the
smart decisions for you’’ (Adult#9). This unanticipated ben-
efit of using a closed-loop system was particularly highlighted
by teenagers and their parents who noted how it had provided
a safety net at a point in the life course when there was greater
potential for self-management to be neglected:
‘‘say I was staying round a friend’s house, cause my mum
worries quite a lot. And like she said that she never really had
to, because she just knew this phone would be sorting me out
like, say I forgot to give myself insulin like it would end up—
like yeah, sorting me out. And everything would like just be
fine.’’ (Adolescent#4)
Participants also noted the additional reassurance gained
from their knowledge that, if blood glucose started to drop too
low, such as after unplanned physical activities had been
undertaken, ‘‘I’ve got the back-up that the closed loop would
have turned the insulin off’’ (Adult#2). However, some par-
ticipants with poor awareness of hypoglycemia and parents of
young children noted that they had needed the pump suspend
feature to be set to a higher threshold to achieve this sense of
hypoglycemic safety.
A more flexible and active life. Due to the level of re-
sponsiveness and perceived hypoglycemic safety offered by
the closed loop, participants noted how this technology had
permitted and enabled a more flexible and spontaneous life.
This included no longer having to stick to regular mealtimes,
as Adult#1 noted, or as Adult#4 described, having to try to
remember to change the pump’s basal settings to mitigate risk
of hypoglycemia when undertaking moderate physical ac-
tivities (Table 4).
Such benefits were particularly noted by parents of youn-
ger children who reported how they had felt, able to give their
child more freedom (e.g., to play with friends, go on school
trips, and attend sleepovers) because both their own and other
people’s (e.g., teachers’) confidence in the child’s safety had
been increased:
‘‘because of the loop we even allowed her to go on a resi-
dential holiday with the school for a week. So the teacher was
confident as well. Yeah, it was good. She could participate
in every single activity at school. She was invited to go to
sleepovers, because people felt confident that she’s gonna be
fine.We could even go out with [friends] as people were
happy to babysit. So yes, we had lots of freedom and confi-
dence.’’ (Parent#4)
Working in partnership with the closed loop
Collaborating with the closed loop to optimize blood
glucose control. While most had anticipated taking a back
seat and allowing the closed loop to regulate blood glucose on
their behalf, only a minority found they had done so in
practice. Most reported how they had been prompted to
continue to take an active role in glycemic management by
the extra data to which they had easy access as a result of
using the system: ‘‘In some ways you think about it less,
cause you think: oh it’s all just being taken care of. But then in
some ways you think about it more because that information
is there to hand’’ (Adult#6). Specifically, participants dis-
cussed how, on occasions, and in light of the CGM alerting
them to blood glucose dropping/rising, they had chosen to
collaborate with the closed loop. Most typically, this col-
laboration had occurred when participants had been alerted to
high blood glucose, had realized this had resulted from an
error (e.g., carbohydrate miscalculation) on their part and had
chosen to administer a corrective dose because the closed
loop ‘‘couldn’t cope with the speed of the rise’’ as Adult#7
noted and as Adult#4 similarly reported:
‘‘So if I can see from the graph my blood glucose increasing,
I’d think: right okay. Oh yeah, I’ve had a cream cake or I’ve
had a biscuit or something I haven’t accounted for. So I’ll just
give it a- I’ll do- based on- based on the bolus wizard—how
much insulin it thinks I need based on that. And I’ll take that
then, knowing that the closed-loop will account for what in-
sulin’s on board. So it just speeds up the correction a little
bit.’’ (Adult#4)
Wanting opportunities to communicate information to the
closed loop. Participants also emphasized the benefits of
being able to understand how the closed-loop system worked
to work with it to increase its effectiveness. To this end, while
being praiseworthy of the system’s ability to learn insulin
requirements based on previous days of learning, some
highlighted a need to communicate information about plans
and intentions on atypical days, such as weekends or holi-
days: ‘‘it’d be much better if I could press a button and say:
I’m really busy today. Don’t be so harsh. Or, I’m having a
really lazy day, you know, brush it up a bit.’’ (Adult#5)
In addition, while liking being able to announce planned
physical activity to the closed loop, some participants sug-
gested that the efficacy of future systems might be improved
by allowing users to discriminate between different intensi-
ties of activity.
‘‘There was a function where you could say: I’m going to be
doing activity for the next half an hour or whatever. but I
couldn’t choose the intensity. So I couldn’t sort of say, you
know.I’m doing high intensity activity. Or I’m just gonna be
walking for the next half an hour, which is quite different to
how it affects your blood sugars.’’ (Adult#5)
Views about education and training and need
for staff support
Training and support needs during the 3-month trial. In
general, participants described the closed-loop system as
having been intuitive, self-explanatory, and easy to use: ‘‘it
was a very easy system to pick up, it was, you know, calibrate
the sensor and press start’’ (Adult#1). Hence, most suggested
that an initial training session had been sufficient to feel able
to start using the system, especially as they had written ma-
terials to refer back to (Table 2).
While initial training was valued, some described how they
had not taken in or retained key information, as its relevance
had only become apparent after they had started using the
closed loop, such as when they first needed to do high-intensity
activity. These individuals highlighted the benefits of receiv-
ing tailored education and trouble-shooting opportunities with
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staff, extending over the first month of use, to help make full
and effective use of the technology (Table 4).
Participants also described valuing opportunities to con-
tact staff by phone and email in the initial weeks of use.
In most cases, this was to resolve technical problems (e.g.,
system errors), which participants suggested were inev-
itable given ‘‘it’s a prototype’’ (Adolescent#5) and which
they believed would be addressed before the system be-
coming commercially available. Many also described
benefitting from glycemic support from staff (e.g., advice
about changing mealtime ratios, basal settings); for instance,
after noting blood glucose repeatedly going low at a partic-
ular time of day.
Longer-term support needs. Individuals also noted how
their need for staff input had generally declined after the
initial month of use and suggested that, were the closed loop
to be introduced into routine clinical care, their need for staff
support after the initial weeks of use, would be no greater
than that required when using a pump:
‘‘I think- the same with any pump that I’ve been on—when I’ve
moved onto a pump I’ve always been like given a number to
call, or if I’ve got any questions, speak to this person. And I
think for the first couple of months you may have questions. But
once you get used to it, you just sort of manage it yourself. So I
don’t think there’d be any change from the support you get on a
closed-loop than you do on a standard pump.’’ (Adult#9)
Discussion
By exploring participants’ experiences of using a hybrid
day-and-night closed-loop system during the day we have
shown that the perceived glycemic and quality-of-life benefits
of overnight systems7–10,12 extend into daytime use. In line
with their initial expectations, and main trial results,21 partic-
ipants were particularly praiseworthy of the system’s ability to
automatically address high and low blood glucose. Other
benefits only became apparent after participants had started to
use the closed loop. These included the system being able to
act as a safety net and mop up errors, such as when mealtime
boluses were forgotten, the carbohydrate content of food was
miscalculated, or unplanned activity was undertaken. In
highlighting these anticipated and unanticipated benefits,
participants also noted how using the closed loop had enabled
them to feel more confident and normal, less burdened by
diabetes, and more able to lead flexible, spontaneous lives.
The benefits of using the closed-loop system were partic-
ularly keenly felt by adolescents and parents who suggested
that it offered a glycemic safety net at a point in life where
diabetes management could be neglected. Indeed, in line with
these participants’ accounts, clinical research has shown that,
in the adolescent age group, a closed-loop system can partly
compensate for boluses being forgotten or miscalculated.22,23
Parents of young children also noted particular benefits
arising from using the closed-loop during the day, including
increased confidence in their child’s safety and, hence, their
being more willing to allow them to participate in activities,
such as going on school trips and playing at friends’ houses.
These findings stand in contrast to those from studies in-
volving parents of children using injection and pump regi-
mens who tend to cocoon and closely supervise their child to
help mitigate concerns about severe hypoglycemia, with a
detrimental impact on both their own and their child’s quality
of life.24
Participants, at baseline, conveyed realistic expectations of
the closed loop, which contrast with findings from earlier
studies where participant expectations of the technology were
high and sometimes unrealistic.3–5 This difference might be
due to some of our participants having previously taken part
in closed-loop research (Table 3). In addition, there is now
much more information about closed-loop systems in the
public domain permitting a greater understanding of the
technology than would have been the case before closed-loop
systems were first developed and trialed. Indeed, participants
in our study described having been exposed to this infor-
mation before the trial.
In keeping with potential users’ expectations,4 participants
reported taking time (typically several weeks) to develop
confidence and trust in the closed-loop system. In doing so,
participants, like users of overnight systems,8 described valuing
having easy access to graphical information, which allowed
them to observe, and understand, how the system worked.
Some also described how, to develop trust, they had needed to
know that the closed-loop-based insulin administration on the
three previous days of use. Hence, it is vital that this informa-
tion about how the closed-loop system works is included and
emphasized in initial training. Users would also benefit from
knowing that the system takes several days to calibrate to their
insulin requirements to help avoid panic, worry, and/or their
taking action which might compromise its learning.
As well as finding individuals take longer to adapt to 24-h
systems than studies of shorter (£5 days) duration have
suggested,2,13,14 our findings challenge assumptions that,
once trust has developed, users will step back and hand over
control to the system.1,14 Contrary to this assumption, most
participants described preferring to collaborate with the
closed loop; for instance, by administering a corrective dose
to help bring down high blood glucose. Participants also
described wanting opportunities to communicate information
to the closed loop, such as when routines changed or a school
holiday started. Given these collaborative opportunities ap-
plied to daytime use, and were only identified over time, it is
unsurprising that they have not been reported in studies in-
volving users of nighttime systems7–12 and 24-h systems used
for short durations.2,13,14
In line with participants’ suggestions, systems could be
developed which allow users to communicate information
about plans and intentions on atypical days and which dis-
criminate between weekdays and weekends. To help prevent
hyperglycemic excursions when doing resistance/high-
intensity training, and hypoglycemic excursions when doing
aerobic/endurance training, systems which allow users to
input information about the intensity and type of planned
activity could also be considered. ‘‘Exercise smart’’ systems,
which automatically receive information about, and respond
to differing levels and durations of physical activity, may also
help address some users’ needs.25,26 Individuals who chose to
have the pump suspend feature set to a higher threshold to
mitigate concerns about hypoglycemia might benefit from
systems which administer glucagon.27,28
While participants valued initial training and input from
staff, including opportunities to contact them to troubleshoot
issues, these were mostly to address technical difficulties
arising from using a prototype. It is also reassuring that, once
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initial adjustments had been made, participants felt their need
for glycemic support was no greater than that required when
using an insulin pump; indeed, their support needs appear
very similar to those reported by participants after converting
to flexible intensive injection and pump regimens.29–31
A key study strength is the use of a qualitative design which
enabled identification of issues which have not previously
been identified in the literature and which could be further
tested and explored in future quantitative research. The 3-
month study period permitted in-depth exploration of how
people used a 24-h system in everyday life and over time,
thereby allowing us to offer a level of insight not previously
reported. However, it is possible that, with longer follow-up,
participants, like CGM users,32 might have experienced
technology fatigue or have had changing needs for health
professional input. As is typical in closed-loop studies, our
sample, which was recruited from a clinical trial, was skewed
toward educated and highly motivated individuals,5,7,9,10,15
which might partly explain their wish to actively engage with
the system. In addition, participants had previous insulin pump
experience, and some had prior experience of using a closed-
loop system, which might have helped expedite their adjust-
ment to, and use of, the technology in the current study. Hence,
future (mixed-methods) studies are recommended. This might
include studies of longer duration, involving use of different
types of closed-loop systems, undertaken in nontrial (i.e.,
routine clinical care) settings, and targeting individuals be-
longing to lower socioeconomic groups. To fully establish
users’ clinical support needs, future evaluations could also
involve quantitative assessment of support solicited and re-
ceived from clinical staff (e.g., measurement of phone and
email contact and frequency of clinic visits).
Conclusion
Our study has demonstrated how, alongside its clinical
benefits,18 closed-loop technology can have a very positive
and meaningful impact on users’ and caregivers’ lives by
enabling them to feel more normal and less burdened by
diabetes. By drawing on participants’ perspectives and ex-
periences over time, we have also identified ways in which
the technology could be further refined and education and
training tailored to optimize effective use.
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